{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coronary+Artery+Disease+Progression",
    "query": {
      "condition": "Coronary Artery Disease Progression"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Coronary+Artery+Disease+Progression&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T02:31:23.429Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00116870",
      "title": "MARS - Monitored Atherosclerosis Regression Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "21 Years to 67 Years"
      },
      "enrollment_count": 270,
      "start_date": "1985-06",
      "completion_date": "1992-02",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116870"
    },
    {
      "nct_id": "NCT01316159",
      "title": "Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Atherosclerosis",
        "Acute Coronary Syndrome",
        "Percutaneous Coronary Intervention",
        "Endothelial Shear Stress",
        "Arterial Remodeling"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 506,
      "start_date": "2007-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-03-16",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01316159"
    },
    {
      "nct_id": "NCT02376010",
      "title": "Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 110,
      "start_date": "2015-04-02",
      "completion_date": "2018-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02376010"
    },
    {
      "nct_id": "NCT00659256",
      "title": "Hepatitis C Treatment and Atherosclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Hepatitis C",
        "Atherosclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2008-04-08",
      "completion_date": "2015-03-24",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659256"
    },
    {
      "nct_id": "NCT03985384",
      "title": "Semaglutide Treatment On Coronary Progression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Semaglutide 2 MG/1.5 ML Subcutaneous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2019-04-30",
      "completion_date": "2022-12-27",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985384"
    },
    {
      "nct_id": "NCT00124332",
      "title": "STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Rimonabant (SR141716)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 839,
      "start_date": "2005-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2009-04-20",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00124332"
    },
    {
      "nct_id": "NCT05708859",
      "title": "Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type II Diabetes",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew J. Budoff",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-01-02",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708859"
    },
    {
      "nct_id": "NCT02966028",
      "title": "Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Cardiovascular Abnormalities",
        "Calcifications, Vascular",
        "Endstage Renal Disease",
        "ESRD",
        "Coronary Artery Calcification"
      ],
      "interventions": [
        {
          "name": "SNF472",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanifit Therapeutics S. A.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 274,
      "start_date": "2016-11",
      "completion_date": "2019-09",
      "has_results": true,
      "last_update_posted_date": "2021-04-15",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 46,
      "location_summary": "Bakersfield, California • Chula Vista, California • Escondido, California + 42 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966028"
    },
    {
      "nct_id": "NCT00225277",
      "title": "Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 547,
      "start_date": "2003-07",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-02-28",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00225277"
    },
    {
      "nct_id": "NCT01612299",
      "title": "Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Zortress® /Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kentucky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2012-05",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-07",
      "last_synced_at": "2026-07-23T02:31:23.429Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01612299"
    }
  ]
}